MedTrace Logo

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

NCT05229640 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-07-13

No results posted yet for this study

Summary

This study proposes to examine the relationship between the development of impaired glucose tolerance, the phenotype of CFLD, and risk of liver fibrosis.

Conditions

  • CF - Cystic Fibrosis
  • Cystic Fibrosis-related Diabetes
  • Cystic Fibrosis Liver Disease

Interventions

DEVICE

Fibroscan

Subjects will fast for at least three hours, then have at least 10 fibroscan readings of their liver.

Sponsors & Collaborators

  • Trustees of Dartmouth College

    collaborator OTHER

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Principal Investigators

  • Mary C. Drinane, MD · Dartmouth-Hitchcock Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2023-06-30
Completion
2023-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229640 on ClinicalTrials.gov